Featured Publications
Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosis
2022
Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives Of Pathology & Laboratory Medicine 2022, 147: 79-86. PMID: 35472771, DOI: 10.5858/arpa.2021-0270-oa.Peer-Reviewed Original ResearchMeSH KeywordsConsensusHodgkin DiseaseHumansImmunohistochemistryKi-1 AntigenLymphoma, T-Cell, PeripheralConceptsCD30 expressionPeripheral T-cell lymphomaClassic Hodgkin lymphomaT-cell lymphomaDifferential diagnostic considerationsHematologists/oncologistsExpert panel consensusCD30 positivityHodgkin's lymphomaPredictive biomarkersDiagnostic workupImmunohistochemistry testingLymphoma biopsiesTherapeutic decisionsDiagnostic considerationsCD30 immunohistochemistryConsensus recommendationsPanel consensusLymphomaPositive expressionBest practice recommendationsImmunohistochemistryTumor cellsPractice recommendationsPanel recommendations
2021
IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias
Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaAcute monocytic leukemiaBlast countCore biopsyMyelomonocytic leukemiaBone marrowPredictive valueMonocytic leukemiaBone marrow core biopsiesCases of AMoLMarrow core biopsiesAcute myeloid leukemia subtypesExpression of IRF8Acute myeloid leukemiaTrephine core biopsiesReliable surface markersDendritic cell progenitorsNegative predictive valuePositive predictive valuePotential biomarker candidatesBlast increaseMonocytic blastsUseful immunostainsBlast percentageReactive monocytosis
2019
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
Maracaja DLV, Puthenpura V, Pels SG, O’Malley D, Sklar JL, Finberg KE, Xu ML. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. Applied Immunohistochemistry & Molecular Morphology 2019, 28: 725-730. PMID: 31789821, DOI: 10.1097/pai.0000000000000820.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorDiagnosis, DifferentialEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryImmunophenotypingKaryopherinsLymphoma, Large B-Cell, DiffuseMaleMediastinal NeoplasmsMutationReceptors, Cytoplasmic and NuclearThymus NeoplasmsYoung AdultConceptsPrimary mediastinal large B-cell lymphomaEpstein-Barr virusLarge B-cell lymphomaB-cell lymphomaEBV positivityMediastinal lymphomaMediastinal large B-cell lymphomaMediastinal gray zone lymphomaGray zone lymphomaRole of immunohistochemistryClassical Hodgkin lymphomaEBV expressionMediastinal massTherapeutic optionsHodgkin's lymphomaClassic immunophenotypeLymphomaXPO1 mutationsMutational profilingPositivityNext-generation sequencingImmunophenotypeSomatic mutationsK mutationTumorsProapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratio
2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaYears of ageFrequent expressionOlder patientsAge cutoffMonoclonal B-cell proliferationArbitrary age cutoffsPoor performance statusGenetic featuresMore frequent expressionB cell proliferationPerformance statusYounger patientsClinicopathologic evidencePatient groupDLBCL patientsTreatment outcomesPatientsDLBCLGene expression profilingCD30Lymphoma
2013
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013, 19: 3462-3473. PMID: 23674495, PMCID: PMC4102335, DOI: 10.1158/1078-0432.ccr-13-0855.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenGene ExpressionHerpesvirus 4, HumanHerpesvirus 8, HumanHodgkin DiseaseHumansImmunohistochemistryLymphomaLymphoma, B-CellConceptsDiffuse large B-cell lymphomaAggressive B-cell lymphomasB-cell lymphomaPosttransplant lymphoproliferative disorderClassical Hodgkin lymphomaLarge B-cell lymphomaPD-L1Hodgkin's lymphomaT-cell/histiocyte-rich B-cell lymphomaExtranodal NK/T-cell lymphomaTissue biopsiesEBV-positive posttransplant lymphoproliferative disordersHistiocyte-rich B-cell lymphomaPD-1/PD-L1 pathwayNK/T-cell lymphomaPD-1/PD-L1Primary mediastinal large B-cell lymphomaNodular lymphocyte predominant Hodgkin lymphomaMixed cellularity classical Hodgkin lymphomaMediastinal large B-cell lymphomaCell death ligand 1Lymphocyte predominant Hodgkin lymphomaPD-L1 protein expressionPD-L1 expressionPD-L1 pathway